TC BioPharm (Holdings) plc develops clinical-stage allogeneic gamma-delta T-cell therapies for cancer and other indications through its American depositary shares. Company news centers on TCB008, its unmodified gamma-delta T-cell product line, and ACHIEVE clinical-trial updates in acute myeloid leukemia, myelodysplastic syndromes/AML, relapse or refractory disease, and minimal residual disease.
Recurring updates also cover use of the company's CryoTC technology for frozen cell-therapy supply, safety and response observations from dosing cohorts, operating changes tied to outsourced production and decentralized drug development, and public-company matters such as ADS trading status and OTC market transition.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.